SUN PHARMA ADVRESCO Latest Share Price (SPARC)
TODAY IN ONE LINE
SPARC slipped 0.5% on light volume, in line with Nifty's -0.3% move.
With a market cap of ₹6,363.87 Cr., it trades at a P/E of 4.02. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
SUN PHARMA ADVRESCO flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Capital EfficiencyROCE of 83.8% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 116.0%
- ●Healthy Operating MarginsOPM is structurally strong at 84.5%
- ●Reasonable ValuationTrading at a moderate P/E of 5.0x
- ●High Promoter HoldingPromoters hold 65.7% skin-in-the-game
- ●FII AccumulationFII holding increased by 1.86% QoQ
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest SUN PHARMA ADVRESCO News
What changed recently?
Recent events, corporate actions, and announcements.
SUN PHARMA ADV.RES.CO.LTD valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for SUN PHARMA ADV.RES.CO.LTD, framed against the sector median so the premium or discount is obvious at a glance.
SUN PHARMA ADV.RES.CO.LTD trades at a P/E of 4.02× and P/B of 4.75×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
SUN PHARMA ADV.RES.CO.LTD technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for SUN PHARMA ADV.RES.CO.LTD — derived from the latest tape, not yesterday's close.
SUN PHARMA ADV.RES.CO.LTD last traded at ₹196.01 with an intraday range of ₹192.56–₹197.55 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹196.01| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 208.17 | +12.16 | +6.20% |
| R3 | 203.18 | +7.17 | +3.66% |
| R2 | 200.36 | +4.35 | +2.22% |
| R1 | 198.19 | +2.18 | +1.11% |
| PIVOT | 195.37 | -0.64 | -0.32% |
| CURRENT | 196.01 | — | — |
| S1 | 193.20 | -2.81 | -1.44% |
| S2 | 190.38 | -5.63 | -2.87% |
| S3 | 188.21 | -7.80 | -3.98% |
| S4 | 183.22 | -12.79 | -6.53% |
SPARC is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: ₹193.31–₹196.89
Trading Below opening range, showing Bearishness
SUN PHARMA ADV.RES.CO.LTD financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for SUN PHARMA ADV.RES.CO.LTD — consolidated or standalone — with margins, YoY growth and key ratios inline.
SUN PHARMA ADV.RES.CO.LTD reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹6,363.87 Cr. and reported EPS of ₹-0.65.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 72 | 1,879 ▲ 2518.3% |
| Sales Growth YoY %Derived | -5.00% | 2,518.32% |
| Other Income | 2 | 11 ▲ 511.7% |
| Total Income | 74 | 1,890 ▲ 2469.5% |
| 23 | 24 ▲ 2.1% | |
| Gross ProfitDerived | 49 | 1,856 ▲ 3714.1% |
| Gross Margin %Derived | 67.79% | 98.74% |
| 372 | 257 ▼ 30.9% | |
| EBITDA (Operating Profit)Derived | -323 | 1,599 ▲ 594.8% |
| OPM %Derived | -450.24% | 85.08% |
| 21 | 32 ▲ 49.2% | |
| Profit Before Tax (PBT) | -343 | 1,553 ▲ 553.1% |
| -0 | -0 ▲ 29.6% | |
| Effective Tax %Derived | 0.08% | -0.01% |
| Total Profit for Period | -343 | 1,553 ▲ 553.5% |
| Net Profit (Owner's PAT)Derived | -343 | 1,553 ▲ 553.5% |
| Net Profit Margin %Derived | -477.23% | 82.65% |
| PAT Growth YoY %Derived | 11.54% | 553.48% |
| Earnings Per Share (EPS ₹) | -10.56 | 47.86 ▲ 553.2% |
| Diluted Shares Outstanding (Cr) | 32 | 32 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | -0 | 3 ▲ 1452.6% |
| Total Expenses (incl. D&A & Interest) | 416 | 337 ▼ 19.0% |
| Material Cost % of RevenueDerived | 32.21% | 1.26% |
| Employee Cost % of RevenueDerived | 213.99% | 6.28% |
| Other Cost % of RevenueDerived | 304.04% | 7.39% |
| Interest Coverage (x)Derived | -37.12x | 46.54x |
| Period | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|
| Revenue from Operations | 76 | 72 ▼ 5.0% | 1,879 ▲ 2518.3% | |
| Sales Growth YoY %Derived | — | -5.00% | 2,518.32% | |
| Other Income | 29 | 2 ▼ 93.9% | 11 ▲ 511.7% | |
| Total Income | 105 | 74 ▼ 30.0% | 1,890 ▲ 2469.5% | |
28 | 23 ▼ 17.8% | 24 ▲ 2.1% | ||
| Gross ProfitDerived | 47 | 49 ▲ 2.6% | 1,856 ▲ 3714.1% | |
| Gross Margin %Derived | 62.77% | 67.79% | 98.74% | |
450 | 372 ▼ 17.3% | 257 ▼ 30.9% | ||
| EBITDA (Operating Profit)Derived | -402 | -323 ▲ 19.6% | 1,599 ▲ 594.8% | |
| OPM %Derived | -532.23% | -450.24% | 85.08% | |
14 | 21 ▲ 50.9% | 32 ▲ 49.2% | ||
| Profit Before Tax (PBT) | -387 | -343 ▲ 11.4% | 1,553 ▲ 553.1% | |
0 | -0 ▼ 171.1% | -0 ▲ 29.6% | ||
| Effective Tax %Derived | -0.10% | 0.08% | -0.01% | |
| Total Profit for Period | -387 | -343 ▲ 11.5% | 1,553 ▲ 553.5% | |
| Net Profit (Owner's PAT)Derived | -387 | -343 ▲ 11.5% | 1,553 ▲ 553.5% | |
| Net Profit Margin %Derived | -512.52% | -477.23% | 82.65% | |
| PAT Growth YoY %Derived | — | 11.54% | 553.48% | |
| Earnings Per Share (EPS ₹) | -11.93 | -10.56 ▲ 11.5% | 47.86 ▲ 553.2% | |
| Diluted Shares Outstanding (Cr) | 32 | 32 ▲ 0.0% | 32 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 0 | -0 ▼ 195.0% | 3 ▲ 1452.6% | |
| Total Expenses (incl. D&A & Interest) | 492 | 416 ▼ 15.4% | 337 ▼ 19.0% | |
| Material Cost % of RevenueDerived | 37.23% | 32.21% | 1.26% | |
| Employee Cost % of RevenueDerived | 187.74% | 213.99% | 6.28% | |
| Other Cost % of RevenueDerived | 407.25% | 304.04% | 7.39% | |
| Interest Coverage (x)Derived | -245.33x | -37.12x | 46.54x |
SUN PHARMA ADVRESCO segment analysis : revenue and profit mix.
Disclosed business segments at SUN PHARMA ADVRESCO with their share of revenue and profit, switchable between consolidated and standalone reporting.
SUN PHARMA ADVRESCO discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for SUN PHARMA ADV.RES.CO.LTD.
Our AI distills the core fundamental drivers supporting SUN PHARMA ADV.RES.CO.LTD, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
SUN PHARMA ADV.RES.CO.LTD's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. The security token included in the request is invalid.
Flip Conditions.
Valuation risk. a P/E above 5 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 111% would indicate weaker capital compounding.
SUN PHARMA ADV.RES.CO.LTD peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — SUN PHARMA ADV.RES.CO.LTD is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
SUN PHARMA ADV.RES.CO.LTD chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for SUN PHARMA ADV.RES.CO.LTD — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
SUN PHARMA ADV.RES.CO.LTD delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for SUN PHARMA ADV.RES.CO.LTD over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in SUN PHARMA ADV.RES.CO.LTD stood at 46.0% of traded volume, against a 20-day average of 42.6%.
SUN PHARMA ADVRESCO announcements: results, concalls, ratings, M&A.
Filings SUN PHARMA ADVRESCO sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
SUN PHARMA ADVRESCO files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 87 documents below.
General Updates
Sun Pharma Advanced Research Company Limited has informed the Exchange about Filing of Application for Reclassification with Stock Exchanges
Copy of Newspaper Publication
Sun Pharma Advanced Research Company Limited has informed the Exchange about Copy of Newspaper Publication
Shareholders meeting
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 10, 2026
Monitoring Agency Report
Sun Pharma Advanced Research Company Limited has informed the Exchange about Monitoring Agency Report for the quarter ended June 30, 2026.
Outcome of Board Meeting
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding Outcome of Board Meeting held on August 10, 2026.
Investor decks & rating reports.
SUN PHARMA ADVRESCO dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue SUN PHARMA ADVRESCO has declared, sequenced by announce and record date.
SUN PHARMA ADVRESCO corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About SUN PHARMA ADV.RES.CO.LTD: business, sector, key facts.
What SUN PHARMA ADV.RES.CO.LTD does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
SUN PHARMA ADV.RES.CO.LTD operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: SPARC, BSE: 532872.
SPARC (Sun Pharma Advanced Research Company Limited) is a clinical-stage biopharmaceutical company headquartered in Mumbai, India, focusing on the research and development of novel pharmaceutical products for global markets. Their core therapeutic areas of concentration are oncology, neurodegeneration, and immunology, reflecting a commitment to addressing significant unmet medical needs across diverse disease areas.
A significant portion of SPARC's business involves advancing a robust pipeline of drug candidates through various clinical trial phases. This includes Elepsia XR for epilepsy, PDP-716 for open-angle glaucoma, and Sezaby for neonatal seizures. These products represent different stages of development, highlighting SPARC's commitment to a diversified approach to drug discovery and development.
In the oncology space, SPARC is actively pursuing the development of Vodobatinib, a c-ABL inhibitor. This compound is in phase 2 clinical trials for Parkinson's disease, has completed phase 1 trials for Lewy body dementia, and is currently in preclinical development for Alzheimer's disease. Further, they are developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, targeting refractory chronic myelogenous leukemia, also in phase 2 clinical trials.
SPARC's commitment to immunology is showcased by the development of Vibozilimod (SCD-044), a selective S1PR1 agonist currently in phase 2 trials for psoriasis and atopic dermatitis. The company also has preclinical stage candidates in development, including SCD-153 for alopecia areata and SBO-154, an anti-MUC-1 antibody-drug conjugate (ADC) targeting multiple tumor types. This demonstrates a long-term strategic vision for growth within this therapeutic area.
In summary, SPARC's business model centers on the innovative research, development, and clinical advancement of a diverse portfolio of pharmaceutical products across several key therapeutic areas. Their pipeline, ranging from preclinical to phase 2 trials, positions them for potential future growth and market expansion in the global biopharmaceutical industry. The company's focus on unmet medical needs underscores its commitment to improving patient outcomes.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Other undervalued NSE stocksScreener
- Quality + Value Portfolio strategyStrategy
- Top quality scorecard stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about SUN PHARMA ADV.RES.CO.LTD (SPARC).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of SUN PHARMA ADV.RES.CO.LTD (SPARC)?
The current share price of SUN PHARMA ADV.RES.CO.LTD (SPARC) is ₹196.01. Today, the stock has declined by ₹0.90 (0.46%), trading in a range of ₹192.56 to ₹197.55. The stock opened at ₹196.89 with a trading volume of 4,75,527 shares.
02Is SUN PHARMA ADV.RES.CO.LTD stock a good investment for long-term?
SUN PHARMA ADV.RES.CO.LTD can be considered for long-term investment based on several factors. The company has a market capitalization of ₹6,363.87 Cr., P/E ratio of 4.02, ROE of 116.01%, and ROCE of 83.81%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of SUN PHARMA ADV.RES.CO.LTD stock?
The 52-week high price of SUN PHARMA ADV.RES.CO.LTD (SPARC) is ₹289.00, while the 52-week low is ₹108.00. Currently trading at ₹196.01, the stock is 81.49% above its 52-week low and 32.18% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy SUN PHARMA ADV.RES.CO.LTD stock at the current price?
Whether to buy SUN PHARMA ADV.RES.CO.LTD stock at ₹196.01 depends on multiple factors. The stock is currently trading with a P/E ratio of 4.02 and P/B ratio of 4.75. Today's performance shows a loss of 0.46%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of SUN PHARMA ADV.RES.CO.LTD and when is the next dividend?
SUN PHARMA ADV.RES.CO.LTD offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹196.01, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of SUN PHARMA ADV.RES.CO.LTD?
SUN PHARMA ADV.RES.CO.LTD's key financial metrics include: P/E Ratio: 4.02, P/B Ratio: 4.75, ROE: 116.01%, ROCE: 83.81%, Dividend Yield: 0%, EPS: ₹-0.65, Book Value: ₹41.26, and Debt-to-Equity: 0.42. The company's market cap stands at ₹6,363.87 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is SUN PHARMA ADV.RES.CO.LTD stock performing today in the market?
SUN PHARMA ADV.RES.CO.LTD stock opened at ₹196.89 and is currently trading at ₹196.01, showing a decline of ₹0.90 (0.46%). The intraday high is ₹197.55 and low is ₹192.56. The trading volume stands at 4,75,527 shares, indicating moderate market participation today.
08What is the P/E ratio of SUN PHARMA ADV.RES.CO.LTD and what does it indicate?
SUN PHARMA ADV.RES.CO.LTD has a Price-to-Earnings (P/E) ratio of 4.02, which means investors are willing to pay 4.02 for every ₹1 of earnings. With an EPS of ₹-0.65, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about SUN PHARMA ADV.RES.CO.LTD (SPARC) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.